Haichuang Pharmaceutical announced that the company received the “Drug Clinical Trial Approval Notice” approved and issued by the Drug Evaluation Center of the State Drug Administration, agreeing to carry out clinical trials using HP568 tablets to treat advanced breast cancer that is positive for estrogen receptors and negative for human epidermal growth factor receptor 2. HP568 is an oral proteolytic targeted conjugate drug independently developed by the company to degrade estrogen receptor α. It consists of a target protein ligand, an E3 ligase ligand, and a ligand 3 parts between the two ligands, and is intended to be used to treat ER+/HER2-advanced breast cancer.

Haichuang Pharmaceutical announced that the company received the “Drug Clinical Trial Approval Notice” approved and issued by the Drug Evaluation Center of the State Drug Administration, agreeing to carry out clinical trials using HP568 tablets to treat advanced breast cancer that is positive for estrogen receptors and negative for human epidermal growth factor receptor 2. HP568 is an oral proteolytic targeted conjugate drug independently developed by the company to degrade estrogen receptor α. It consists of a target protein ligand, an E3 ligase ligand, and a ligand 3 parts between the two ligands, and is intended to be used to treat ER+/HER2-advanced breast cancer.